# FIL Study on ABVD DD-DI as Upfront Therapy in HL.

> **NCT03159897** · PHASE3 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 500 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Bleomycin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT03159897
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2021-11-02
- **Final completion:** 2024-11-03
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03159897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03159897, "FIL Study on ABVD DD-DI as Upfront Therapy in HL.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03159897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*